26 March 2013

Eisai to establish new sales and marketing operation in Russia

Hatfield, England - 26 March 2013 - Eisai EMEA (Europe, Middle East and Africa) plans to establish a new sales and marketing operation in Russia based in Moscow. Eisai's market entry will be based on launching its in-house developed innovative breast cancer treatment, Halaven™ (eribulin). The launch is expected to be during Q2 2013. Following this, Eisai expects to launch its epilepsy portfolio including: Zonegran® (Zonisamide), Exalief® (eslicarbazepine acetate), and will seek regulatory approval of Fycompa® (perampanel) and Inovelon® (rufinamide).

The Russian healthcare market is large and one of the fastest growing in the world. The pharmaceutical industry has seen significant expansion over the last few years and it holds strong potential for double-digit growth in the next six years. The value of goods and services on the Russian pharmaceutical market is expected to reach USD 22.1 billion by 2016. Analysts estimate that, by 2020, the Russian pharmaceutical market is expected to reach a value of $60 billion, with annual growth rates of at least 15 percent. 

Commenting on the planned market entry, Gary Hendler, Eisai President & CEO, Russia and EMEA, said: "Eisai's entry into Russia is fully aligned with the company's wider strategy of establishing a solid foundation in the EMEA region. We currently have a number of products in the final stages of approval and hope to launch four to five products within a year of market entry. This will allow Russian patients' to have access to innovative treatments not previously available to them and further supports Eisai's human health care (hhc) mission to satisfy unmet medical needs and contribute to the health and well-being of people worldwide." 

Eisai is a leading research and development (R&D) based pharmaceutical company. With operations in the U.S., Asia, Europe and its domestic home market of Japan, Eisai employs more than 11,000 people worldwide. From its Europe based Knowledge Centre in Hatfield, UK, Eisai has recently expanded business operations to include the expanded territory of Europe, the Middle East, Africa and Russia (EMEA). Eisai EMEA undertakes sales and marketing operations in over 20 markets. 

Source: Eisai Europe Limited / PRNewswire